½ÃÀ庸°í¼­
»óǰÄÚµå
1530007

½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Cardiac Mapping Devices Market Size, Share & Trends Analysis Report, By Type, By Indication, By End Use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, IncÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 9.1%ÀÇ CAGRÀ» ±â·ÏÇÏ¿© 2030³â¿¡´Â 36¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ºÎÁ¤¸Æ »ç·Ê ¹× ½ÉÀå ¼ö¼ú ȯÀÚ ¼ö Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀü, Á¤ºÎ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê µîÀÌ ÀÖÀ¸¸ç, 2023³â 8¿ù¿¡ ¹ßÇ¥µÈ Heart Rhythm SocietyÀÇ ³í¹®¿¡ µû¸£¸é, ½É¹æ¼¼µ¿(AFib) Àº °¡Àå ÈçÇÑ ½ÉÀå ºÎÁ¤¸ÆÀ¸·Î, ¹Ì±¹ ³» 6¹é¸¸ ¸íÀ» Æ÷ÇÔÇØ Àü ¼¼°èÀûÀ¸·Î ¾à 4,000¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

40¼¼ ÀÌ»ó ¼ºÀÎ 4¸í Áß 1¸íÀº ½É¹æ¼¼µ¿ ¹ßº´ À§ÇèÀÌ ÀÖÁö¸¸, ¸¹Àº »ç¶÷µéÀÌ ½É¹æ¼¼µ¿ÀÇ Áõ»ó, Ä¡·á¹ý, ÁøÇàÀ» ¸·±â À§ÇÑ Á¶±â °³ÀÔÀÇ Á߿伺¿¡ ´ëÇØ Àß ¾ËÁö ¸øÇÕ´Ï´Ù. ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛÀÇ ¹ßÀüµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 6¿ù¿¡´Â ½É¿Ü¸·¿¡¼­ ½ÉÀåÀÇ µ¿¸Æ°ú Á¤¸ÆÀ» °¡·ÎÁú·¯ ¸ÅÇÎÇÏ´Â ´ÙÁß Àü±Ø ¹Ù±¸´Ï¿Í Ä«Å×ÅÍ¿Í °°Àº »õ·Î¿î ¸ÅÇÎ ±â¼úÀÌ µîÀåÇÏ¿© Áø°ø Ä¡·á Áß 3Â÷¿ø Ȱ¼ºÈ­ ½ÃÄö½º¸¦ Á¤ÀÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÄÄÇ»ÅÍ ºñÁ¢ÃË ¸ÅÇÎÀº ½É±Ù ³»¸·À» Á÷Á¢ ¸¸ÁöÁö ¾Ê°í ¼öÇÐÀû ¾Ë°í¸®ÁòÀ» »ç¿ëÇÏ¿© ÀüÀ§µµ¸¦ À籸¼ºÇÏ¿© 3 Â÷¿ø µîÀüÀ§µµ¸¦ »ý¼ºÇÕ´Ï´Ù.

½ÉÀå Àü±â»ý¸®ÇÐÀÇ ¿ø°Ý ¸ð´ÏÅ͸µ ¹× °¨¿° ¿¹¹æÀÇ ¹ßÀüÀº ÀÓ»ó ÇöÀå ¹Û¿¡¼­µµ ȯÀÚÀÇ ½ÉÀå ¹Úµ¿À» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ¿© ½Å¼ÓÇÑ Ä¡·á Á¶Á¤À» °¡´ÉÇÏ°Ô Çϰí ħ½ÀÀû ½Ã¼ú·Î ÀÎÇÑ °¨¿° À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷µéÀÇ Àü·«Àû ³ë·Âµµ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Á¸½¼¾ØµåÁ¸½¼ÀÇ ¹ÙÀÌ¿À¼¾½º À¥½ºÅÍ(Biosense Webster)´Â 2024³â 7¿ù Æ®·ç·¹ÇÁ(TrueRef) ±â¼úÀÌ Àû¿ëµÈ ¸ÅÇÎ Ä«Å×ÅÍ ¿ÉÆ®·¼(Optrell)À» Ãâ½ÃÇß½À´Ï´Ù. ¹ÙÀÌ¿À¼¾½º À¥½ºÅͰ¡ ͏®Æ÷´Ï¾Æ ¾î¹ÙÀο¡¼­ ¼³°èÇÑ ¿ÉÆ®·¼Àº Ä«Åä 3 ½Ã½ºÅÛ°ú ÅëÇÕµÈ °í¹Ðµµ Áø´Ü Ä«Å×ÅÍÀÔ´Ï´Ù. ¼ÒÇü Àü±ØÀ» °íÁ¤µÈ ¾î·¹ÀÌ ÇüÅ·Π¹èÄ¡ÇÏ¿© º¹ÀâÇÑ ºÎÁ¤¸ÆÀÇ Á¤È®ÇÑ Àü±â»ý¸®ÇÐÀû ¸ÅÇÎÀ» ¼öÇàÇÕ´Ï´Ù.

½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¢ÃË½Ä ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛ ºÐ¾ß´Â ±â¼ú ¹ßÀü, ÁÖ¿ä ±â¾÷ÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, ½ÉÀå ¼ö¼ú·® Áõ°¡·Î ÀÎÇØ 2023³â 57.07% ÀÌ»óÀÇ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ½É¹æ¼¼µ¿ ºÎ¹®Àº ºÎÁ¤¸Æ ȯÀÚ Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ 2023³â 45.87% ÀÌ»óÀÇ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • º´¿ø ºÎ¹®Àº 2023³â 69.38%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. º´¿øÀº ÷´Ü ½ÉÀå ¸ÅÇÎ ±â±â¿Í °°Àº ½Å±â¼úÀ» äÅÃÇÏ°í Æò°¡ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ¸¦ ÅëÇØ º´¿øÀº ½ÉÀå ºÎÁ¤¸Æ ȯÀÚ¿¡°Ô ÃÖ÷´Ü Ä¡·á¸¦ Á¦°øÇÏ¿© ´õ ³ªÀº °á°ú¸¦ º¸ÀåÇϰí Àü±â »ý¸®ÇÐ ºÐ¾ß¸¦ ¹ßÀü½Ãų ¼ö ÀÖ½À´Ï´Ù.
  • ºÎÁ¤¸ÆÀ» Æ÷ÇÔÇÑ ½ÉÇ÷°ü Áúȯ(CVDs) ȯÀÚ ¼ö Áõ°¡·Î ÀÎÇØ ºÏ¹Ì´Â 2023³â ¼¼°è ½ÃÀå¿¡¼­ 41.39%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼°èÀÇ ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : À¯Çü ´ë½Ãº¸µå
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
  • Á¢ÃËÇü ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛ
  • ºñÁ¢ÃËÇü ½ÉÀå ¸ÅÇÎ ½Ã½ºÅÛ

Á¦5Àå ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ÀûÀÀÁõ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ÀûÀÀ ´ë½Ãº¸µå
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ÀûÀÀ º¯µ¿ ºÐ¼®
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, ÀûÀÀÁõº°, 2018-2030³â
  • ½É¹æ¼¼µ¿
  • ½É¹æÁ¶µ¿
  • ±âŸ

Á¦6Àå ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµ ´ë½Ãº¸µå
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • º´¿ø
  • Áø´Ü ¼¾ÅÍ
  • ±âŸ

Á¦7Àå ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : ±¹°¡, À¯Çü, ÃÖÁ¾ ¿ëµµ, ÃÖÁ¾ ¿ëµµº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¼¼°èÀÇ ½ÉÀå ¸ÅÇÎ ±â±â ½ÃÀå : Áö¿ª ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018³â¿¡¼­ 2030³â
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï »óȲ

  • ÁÖ¿ä Á¦Á¶¾÷ü¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀï ºÐ·ù
  • º¥´õ »óȲ
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Abbott
    • Medtronic
    • BIOTRONIK
    • Acutus Medical
    • APN Health, LLC
    • Johnson & Johnson
    • Biosig Technologies, Inc.
    • Boston Scientific Corporation
    • Kardium, Inc.
    • Koninklijke Philips NV
    • Microport Scientific Corporation
ksm 24.08.23

Cardiac Mapping Devices Market Growth & Trends:

The global cardiac mapping devices market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving the market expansion include the rising arrhythmia cases & number of cardiac surgery patients, growing geriatric population, technological advancements in cardiac mapping systems, and supportive government initiatives. According to the Heart Rhythm Society article published in August 2023, Atrial fibrillation (AFib), the most common type of cardiac arrhythmia, affects nearly 40 million people worldwide, including 6 million in the U.S. Its widespread prevalence underscores the need for advanced diagnostic and treatment options.

Approximately 1 in 4 adults over 40 are at risk of developing AFib, yet many are unaware of its symptoms, available treatments, and the importance of early intervention to prevent progression. Advancements in cardiac mapping systems also drive market growth. For instance, in June 2024, new mapping techniques, such as multielectrode baskets and catheters mapping across cardiac arteries and veins on the epicardium, enabled three-dimensional activation sequence definition during vacuum therapy. Computerized non-contact mapping uses mathematical algorithms to reconstruct electrograms and generate three-dimensional isopotential maps without direct heart endocardium contact.

Advances in remote monitoring and infection prevention in cardiac electrophysiology support continuous patient heart rhythm monitoring outside clinical settings, allowing prompt treatment adjustments and reducing invasive procedure infection risks. Moreover, several strategic initiatives by key players fuel the market's growth. For instance, in July 2024, Johnson & Johnson's Biosense Webster launched the Optrell mapping catheter, incorporating TrueRef technology. Designed in Irvine, California, by Biosense Webster, Optrell is a high-density diagnostic catheter that integrates with the Carto 3 system. It utilizes small electrodes in a fixed array configuration to provide accurate electrophysiological mapping for complex cardiac arrhythmias.

Cardiac Mapping Devices Market Report Highlights:

  • The contact cardiac mapping systems segment held the largest share of over 57.07%, in 2023 due to technological advancements, strategic initiatives by key players, and a rising volume of cardiac procedures
  • The atrial fibrillation segment held the largest share of over 45.87% in 2023 due to increased cases of arrhythmia and high geriatric population
  • The hospitals segment held the largest share of 69.38% in 2023. Hospitals play a vital role in adopting and assessing new technologies, such as advanced cardiac mapping devices. These devices enable hospitals to deliver state-of-the-art care for patients with cardiac arrhythmias, ensuring better outcomes and advancing the field of electrophysiology
  • North America dominated the global market with a share of 41.39% in 2023 owing to the increased cases of cardiovascular diseases (CVDs), including arrhythmias. Product launches, regulatory approvals, and advanced healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Indication
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecast timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Segment
    • 2.2.2. Indication Segment
    • 2.2.3. End-use Segment
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Cardiac Mapping Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing number of cardiac surgery patients
      • 3.2.1.2. Rising arrhythmia cases
      • 3.2.1.3. Technological advancements in mapping systems
      • 3.2.1.4. Growing number of cardiovascular diseases (CVD)
      • 3.2.1.5. Rising geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of cardiac mapping systems
      • 3.2.2.2. Lack of adequate infrastructure
  • 3.3. Cardiac Mapping Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cardiac Mapping Devices Market: Type Estimates & Trend Analysis

  • 4.1. Cardiac Mapping Devices Market: Type Dashboard
  • 4.2. Cardiac Mapping Devices Market: Type Movement Analysis
  • 4.3. Cardiac Mapping Devices Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Contact cardiac mapping systems
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Non-contact cardiac mapping systems
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Cardiac Mapping Devices Market: Indication Estimates & Trend Analysis

  • 5.1. Cardiac Mapping Devices Market: Indication Dashboard
  • 5.2. Cardiac Mapping Devices Market: Indication Movement Analysis
  • 5.3. Cardiac Mapping Devices Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Atrial Fibrillation
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Atrial Flutter
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Cardiac Mapping Devices Market: End Use Estimates & Trend Analysis

  • 6.1. Cardiac Mapping Devices Market: End Use Dashboard
  • 6.2. Cardiac Mapping Devices Market: End Use Movement Analysis
  • 6.3. Cardiac Mapping Devices Market Size & Forecasts and Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Centers
    • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Cardiac Mapping Devices Market: Regional Estimates & Trend Analysis by Country, Type, End-use, & End Use

  • 7.1. Global Cardiac Mapping Devices Market: Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Regulatory framework/ reimbursement structure
      • 7.3.4.3. Competitive scenario
      • 7.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.9. Denmark
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Regulatory framework/reimbursement structure
      • 7.4.9.3. Competitive scenario
      • 7.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.3. South Africa
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Abbott
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Medtronic
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. BIOTRONIK
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Acutus Medical
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. APN Health, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Johnson & Johnson
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Biosig Technologies, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Boston Scientific Corporation
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Kardium, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Koninklijke Philips N.V
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Microport Scientific Corporation
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦